homefeedbacksupportlog on 6-Jul-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


David Back
University of Liverpool, United Kingdom

Faculty Member: PHARMACOLOGY & DRUG DISCOVERY > Antimicrobial agents [ since 7 August 2006 ]
[ Evaluations ]
to email [Help]
Evaluations

The Effect of Atazanavir and Atazanavir/Ritonavir on UDP-Glucuronosyltransferase Using Lamotrigine as a Phenotypic Probe.
Burger D, Huisman A, …, Koopmans P, Bertz R
Clin Pharmacol Ther 2008 Jun 4 [abstract on PubMed] [related articles] [full text]
Selected by | David Back
Evaluated 18 Jun 2008

Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
Hofmann MH, Blievernicht JK, …, Schwab M, Zanger UM
J Pharmacol Exp Ther 2008 Apr 325(1):284-92 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 23 Apr 2008

HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S, Phillips E, …, Benbow A, PREDICT-1 Study Team
N Engl J Med 2008 Feb 7 358(6):568-79 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Frank Christiansen / David Back
Evaluated 17 Mar 2008


Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
van der Lee M, Sankatsing R, …, Reiss P, Burger D
Antivir Ther 2007 12(7):1127-32 [abstract on PubMed] [related articles] [order article]
Selected by | David Back
Evaluated 9 Jan 2008

Lopinavir-Ritonavir Dramatically Affects the Pharmacokinetics of Irinotecan in HIV Patients With Kaposi's Sarcoma.
Corona G, Vaccher E, …, Innocenti F, Toffoli G
Clin Pharmacol Ther 2007 Aug 22 [abstract on PubMed] [related articles] [full text]
Selected by | David Back
Evaluated 11 Oct 2007

The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients.
Kiser J, Carten M, …, Bushman L, Fletcher C
Mol Ther 2008 Feb 83(2):265-72 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 13 Jul 2007

HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
Shuter J, Sarlo JA, …, Rode RA, Zingman BS
J Acquir Immune Defic Syndr 2007 May 1 45(1):4-8 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 29 May 2007

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.
Josephson F, Allqvist A, …, Haefeli WE, Bertilsson L
Clin Pharmacol Ther 2007 May 81(5):708-12 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 25 Apr 2007

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
Hogeland GW, Swindells S, …, Yee GC, Lindley CM
Clin Pharmacol Ther 2007 Jan 81(1):69-75 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 29 Jan 2007

Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication.
De Rijck J, Vandekerckhove L, …, Christ F, Debyser Z
J Virol 2006 Dec 80(23):11498-509 [abstract on PubMed] [related articles] [FREE full text]
Selected by | David Back
Evaluated 6 Dec 2006

Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Gingelmaier A, Kurowski M, …, Friese K, Grubert TA
AIDS 2006 Aug 22 20(13):1737-43 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 5 Dec 2006

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Burger DM, Agarwala S, …, Wang Y, Bertz R
Antimicrob Agents Chemother 2006 Oct 50(10):3336-42 [abstract on PubMed] [related articles] [FREE full text]
Selected by | David Back
Evaluated 18 Oct 2006

Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
Corbett AH, Patterson KB, …, Lim ML, Kashuba AD
Antimicrob Agents Chemother 2006 Aug 50(8):2756-61 [abstract on PubMed] [related articles] [FREE full text]
Selected by | David Back
Evaluated 22 Sep 2006

Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects.
van der Lee MJ, Dawood L, …, Koopmans PP, Burger DM
Clin Pharmacol Ther 2006 Aug 80(2):159-68 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Back
Evaluated 21 Sep 2006

^Top  Back to Faculty Members


© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info